Laryngeal cancer is one of the cancers of the upper aero-digestive tract and accounts for 3% of cancers in humans worldwide [1] [2]. In the majority of cases, it affects men with a sex ratio of 8 men to 2 women [2]. It mainly occurs between 45 and 70 years [2]. Worldwide, there are 238,000 new cases each year and 106,000 deaths annually [3]. In North America and the United States in particular, there are approximately 13,000 cases and 3660 deaths each year due to laryngeal cancer [3]. In Europe, the incidence of laryngeal cancer in men in 2012 was 35,981 cases with a mortality of 18,069 of these cases [4]. In French-speaking Africa, its incidence is 0.6 per 100 inhabitants [4]. For a patient with cancer of the larynx, clinical examination, imaging and endoscopy under general anesthesia, and histology are essential to establish the diagnosis, study the tumor and its extensions, look for metastatic lymphadenopathy and synchronous localization [1]. The most frequent histopathological form is squamous cell carcinoma and accounts for 95% of laryngeal cancers [5]. Its treatment depends on the evolutionary stage of the tumor and poses the challenge of laryngeal preservation. This treatment oscillates between very aggressive amputation surgery and still promising chemoradiotherapy, without omitting the role of prevention as a definite therapeutic component [6]. Several factors are associated with the occurrence of these cancers, but tobacco is so far the most incriminated factor with a presence in 98% of patients [7]. The prognosis of laryngeal cancer is linked to several factors. Thus the site of the cancer, the age and sex of the patient, the TNM stage, the association of laryngeal cancer with other non-neoplastic pathologies and anemia have been identified in North America, Europe and Asia, and in some African countries [6] [8] [9]. The overall survival rate of patients worldwide is between 66% - 89.7% all stages combined [6]. In North America, a Canadian study shows that it is 62% at 5 years [10]. In Europe, the net survival in France is 61.6% at 5 years [11]. In Africa, a study done in Morocco on glottal cancer reports a survival rate of 77% [12]. In Cameroon, a few studies have been carried out on laryngeal cancer, namely a study carried out by Mvouni et al. in 2006 which found a 3-year survival rate close to 21% [13]. It emerges from the above that few studies have been devoted to laryngeal cancer, hence our interest in studying this pathology and in particular on prognostic factors and patient survival.

This was a retrospective cohort study conducted among laryngeal cancers patients at the ENT, oncological, anatomopathological, radiotherapy and surgeryDepartment of three reference health structures in the cities of Douala and Yaoundé (Laquintinie Hospital and General Hospital of Douala, General Hospital of Yaounde), were retrospectively retrieved from the medical records of those department databases with a 100% rate of accuracy, from January 1, 2009 to December 31, 2018. We carried out non-probability sampling. Records showing complete clinical examination, indicating the presence of malignant tumour in the larynx were included. Patients with other laryngeal conditions and histopathological confirmed non-malignanttumours were excluded. The information was collected on a data collection sheet that we designed, pre-tested and readjusted according to the dysfunctions observed. A trained medical staff took part in this collection. The different sociodemographic, clinical, paraclinical, therapeutical and evolutive data were filled in the questionnaires and the patients or their relatives contacted through phone calls in order to know their vital states and complete all possible lacking information. This information was registered and processed using SPPS version 20 software and Microsoft Excel 2016. We carried out a descriptive analysis of the studied population, the different associations between clinicopathological variables and tumour location was performed using the χ2 test. or Fisher’s exact test. Univariate analysis was performed by performing the survival curves according to the Kaplan-Meier method and the difference in survival was compared statistically by the Log Rank test. Variables statistically significant in univariate analysis were secondarily introduced into the Cox regression model for multivariate analysis. Statistical significance was set at a value of p < 0.05.

This work had received an ethical clearance from the Ethics Committee of the University of Douala, who granted us ethical clearance No 2108 CEI-UDo/07/2020/T, to conduct our study in strict compliance with the ethics.

We collected data in 111 files of patients with laryngeal cancer whose diagnosis was made between January 1, 2009 and December 31, 2018. Among the 111 files recruited, 31 files were excluded according to the inclusion criteria. Thus, 80 patients were found for our study.

In our study, the one-year, three-year, five-year, and eight-year overall survival rates are 70%, 18%, 3%, and 1.5%, respectively. Our overall one-year survival is similar to that found by Daneshi et al. in Iran for whom, the patients’ 1-, 3-, 5-, and 10-year survival rates were 81%, 62%, 53%, and 38%, respectively; in USA, the 5-year relative survival rate was 46% for Supraglottis location, 76% for Glottis and 52% for subglottis [14] [15]. But these results are lower than those of Zhang et al. in China with 99% and 100% respectively [16]. Our lower survival rate than that in the literature could be explained by the advanced stages consultation of our patients during the disease.

Our overall three-year survival is 18%, it was higher than the overall survival rate in Brazzaville, which was estimated at 15% [17]. But, our result is lower than those found by Balakrishna (45.7%), Santos (61.4%), Daneshi (62%), even Zhang et al. in China in 2013 [with a rate of 81.5%, [14] [16] [18] [19]. In another study, the 3-year survival rate for advanced stage was 61% [20]. This discrepancy between our series and the results of the literature could be explained by the non-compliance of patients, the non-compliance with medical monitoring for various reasons and the late diagnosis of the disease.

The overall five-year survival in our series is 3%. Pezier et al. reported a 35.6% survival rate among American patients after 5 years of diagnosis, another study in the USA reported the 5-year survival rate of the patients as 53%, [21] [22]. Daneshi reported about 53% which is far below the data found in the literature [14]. The discrepancy between our series and the literature could be explained by the small size of our sample, the advanced stage during the diagnosis in our patients and the late diagnosis in the latter.

After analysis of the survival curves by the Log-Rank test, the factors that influenced survival in our study were: age, stage (TNM), presence of metastasis, surgical resection margin, type of treatment and consultation delay. These results agree with those of Boffeta et al. in Italy who found lymph node involvement, TNM stage, age, smoking and the location of the tumor [23]. Daneshi discovered significant relationship between patients’ survival and age at diagnosis, disease stage, tumor grade, positive L. node, and type of treatment [14]. Brandstorp-Boesen et al. by studying Impact of stage, management and recurrence on survival rates in laryngeal cancer, revealed that, concerning the glottic cancer, surgical treatment improved overall survival, whereas old age, alcohol, T3-T4 status, positive N-status and no treatment were associated with worse survival. In supraglottic, age, alcohol, and positive N-status had a significant impact on overall survival by multivariate analysis [24]. Zhang et al. also discovered that the surgical resection margin, clinical stage, and comorbidity were independent factors affecting the laryngeal cancer prognosis [16].

A study by Gourin et al. on patients with stage 4 of LC suggested that those with a higher N stage were at a greater risk of death. Accordingly, the risk of death in people at N2 and N3 stages was 2.29 and 2.96 times more than those at a N0 stage

The factors found above, influencing survival in our series, were re-analyzed according to the Cox model in order to estimate the Hazard Ratio. The resulting prognostic factors are: age: ≥ 70 (HR = 19.52, p = 0.027) as a factor of poor prognosis; Surgical treatment associated with neoadjuvant chemotherapy (HR = 0.42, p = 0.039) and Surgical treatment associated with neo-adjuvant radiotherapy (HR = 0.45, p = 0.019) as a factor of good prognosis. In most studies on the survival of patients with LC, age was considered as an important risk factor. Daneshi et al. illustrated that the risk of death in patients aged between 50 and 70 and patients over 70 was, respectively, 1.77 and 3.69 times more than those under 50 [14]. In a series of 1030 head and neck cancer patients, Lacy et al found that younger patients had a significantly better five year survival rate than middle aged or old patients [25]. Brandstorp-Boesen et al. in the study of supraglottic LSCC revealed that older age (>60 years) was a significant negative prognostic factor [24]. Boffeta et al. in Italy concluded that patients in older age groups experienced significantly worse survival than younger patients, the difference being particularly relevant between patients aged < 70 years at diagnosis and those aged > 70 years at diagnosis [23]. Some others authors found no significant relationship between age and the risks of death [21] [26]. The advanced age would be a factor of poor prognosis could be justified first of all by the fact that the patients drag this pathology for a long time and thus arrive at advanced stages and should be noted that the more the patients age the lesser the support of side effects of different treatments

According to Bradford et al., Surgery and radiotherapy, either alone or in combination, are the conventional modalities for the management of squamous cell carcinoma of the larynx; in squamous cell carcinoma, chemotherapy in conjunction with radiotherapy is an alternative to laryngectomy in patients with advanced larynx cancer [9]. Wolf et al. found that good survival rates were achieved in patients selected for primary surgery, and both neoadjuvant chemotherapy and primary surgery had better survival rates than with concurrent chemoradiotherapy. Although the optimal individualized treatment approach for patients with advanced laryngeal cancer has not yet been defined, and likely does include surgery [27]. In the series of Iseh and Kufreh in 2011 in Nigeria, the combination of surgery and radiotherapy was a good prognostic factor as in our series [28]. The combination of surgery-radiotherapy, surgery-chemotherapy will have an advantage of limiting and controlling the evolution of the tumor, increasing the chances of completing remission and reducing recurrence and metastasis.

Our study concerned patients with laryngeal cancer in Cameroon, particularly in the cities of Yaoundé and Douala, and at the end of our recruitment we retained 80 patients out of the 101 files found between 10 years. During this study, we were stuck with problems such asthe absence and/or insufficiency of key information for our study: patient history, clinical examination data, anatomopathological, biological and morphological examination results. Notwithstanding these limiting parameters of our study, we nevertheless succeeded in identifying the prognostic factors and the survival of patients with laryngeal cancer in the Yaounde General Hospitals, Douala Gneral Hospital and Douala Laquintinie Hospital.

Present study showed that survival in laryngeal cancer in Cameroon is very low with a median overall survival of 1.41 years. The overall survival rates at 1 year, 3 years, 5 years and 8 years are 70%, 18%, 3% and 1.5%, respectively. The age greater than or equal to 70 years is the poor prognosis factor, while receiving surgery in combination with neoadjuvant chemotherapy or surgery in combination with adjuvant radiotherapy is the factor of good prognosis.

The authors declare no conflicts of interest regarding the publication of this paper.

Engbang, J.P., Mpessa, M., Essama, L., Mohamadou, S.A. and Njock, L.R. (2021) Prognostic Factors and Survival of Laryngeal Cancer in Cameroon. International Journal of Otolaryngology and Head & Neck Surgery, 10, 30-42. https://doi.org/10.4236/ijohns.2021.101004